A Biomarker for Timing Kidney Support in Critically Ill Children
A new study in Pediatric Research investigates the potential of urine neutrophil gelatinase–associated lipocalin (NGAL) to guide the duration of continuous kidney support therapy (CKST) in pediatric acute kidney injury (AKI). The research, a secondary analysis of two prospective cohorts, found that higher NGAL levels early in treatment were associated with a longer required duration of CKST. Conversely, lower NGAL levels measured near the time of therapy discontinuation strongly predicted successful and sustained liberation from the support system. This work addresses a critical gap in clinical decision-making, where stopping CKST currently relies on subjective physiological markers rather than objective molecular diagnostics of tubular injury and recovery.
Study Significance: For pathologists and clinical laboratories, this research underscores the evolving role of specific biomarkers like NGAL in moving beyond simple diagnosis towards guiding dynamic treatment decisions. It highlights a practical application of molecular pathology where a quantifiable analyte could directly inform therapeutic management and improve diagnostic accuracy in a complex clinical setting. Integrating such biomarker data into laboratory reporting could help standardize care and optimize resource use in critical care nephrology.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
